| 免疫检查点抑制剂耐药机制的研究进展 |
| |
| 引用本文： | 张兰兰,李向敏,樊再雯. 免疫检查点抑制剂耐药机制的研究进展[J]. 肿瘤防治研究, 2020, 47(8): 636-640. DOI: 10.3971/j.issn.1000-8578.2020.19.1491 |
| |
| 作者姓名： | 张兰兰 李向敏 樊再雯 |
| |
| 作者单位： | 1. 100142 北京,空军特色医学中心肿瘤内科;2. 075000 张家口,河北北方学院研究生学院临床医学系 |
| |
| 基金项目： | 北京市科学技术委员会资助项目（Z171100000417029） |
| |
| 摘 要： | 肿瘤免疫治疗尤其是免疫检查点抑制剂（ICI）治疗已成为目前肿瘤治疗研究领域的热点。随着ICI在肿瘤领域广泛应用,ICI治疗给人类带来新的希望,但是真实世界里的数据显示：部分患者从中获益,部分患者治疗有效一段时间后,病情出现进展或复发,还有部分患者一开始就对ICI治疗无应答,因此可以将ICI的耐药分为原发性、适应性和获得性耐药。本文就肿瘤ICI治疗的各耐药机制作一综述。
|
| 关 键 词： | 肿瘤 免疫检查点抑制剂 免疫治疗 耐药机制 |
| 收稿时间： | 2019-12-03 |
Advance in Drug Resistance Mechanism of Immune Checkpoint Inhibitors |
| |
| ZHANG Lanlan,LI Xiangmin,FAN Zaiwen. Advance in Drug Resistance Mechanism of Immune Checkpoint Inhibitors[J]. Cancer Research on Prevention and Treatment, 2020, 47(8): 636-640. DOI: 10.3971/j.issn.1000-8578.2020.19.1491 |
| |
| Authors: | ZHANG Lanlan LI Xiangmin FAN Zaiwen |
| |
| Affiliation: | 1. Department of Oncology, Air Force Medical Center, PLA, Beijing 100142, China; 2. Department of Clinical Medicine, Graduate College, Hebei North University, Zhangjiakou 075000, China |
| |
| Abstract: | At present, immune-therapy, especially immune checkpoint inhibitors(ICI) therapy, has become a hot topic in cancer research field. With the wide application of ICI in the field of cancer, some patients benefit from ICI, some patients appeared disease progression or recurrence after effective treatment for a period of time and some patients did not respond to ICI in the first place. The resistance to ICI can be classified into primary, adaptive and acquired resistance. This article will review those resistance mechanisms of ICI therapy. |
| |
| Keywords: | Tumor Immune-checkpoint inhibitors(ICI) Immunotherapy Resistance mechanism |
|
| 点击此处可从《肿瘤防治研究》浏览原始摘要信息 |
|
点击此处可从《肿瘤防治研究》下载全文 |
|
